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DNA damageNeuropeptide S (NPS) and its receptor were recently discovered in the central nervous system. In rodents,
NPS promotes hyperlocomotion, wakefulness, anxiolysis, anorexia, and analgesia and enhances memory
when injected intracerebroventricularly (i.c.v.). Herein, NPS at different doses (0.01, 0.1 and 1 nmol) was
i.c.v. administered in mice challenged with pentylenetetrazole (PTZ; 60 mg/kg) repeatedly injected. Aiming
to assess behavioral alterations and oxidative damage to macromolecules in the brain, NPS was injected
5 min prior to the last dose of PTZ. The administration of NPS only at 1 nmol increased the duration of sei-
zures evoked by PTZ, without modifying frequency and latency of seizures. Biochemical analysis revealed
that NPS attenuated PTZ-induced oxidative damage to proteins and lipids in the hippocampus and cerebral
cortex. In contrast, the administration of NPS to PTZ-treated mice increased DNA damage in the hippocam-
pus, but not cerebral cortex. In conclusion, this is the ﬁrst evidence of the potential proconvulsive effects of
NPS in mice. The protective effects of NPS against lipid and protein oxidative damage in the mouse hippocam-
pus and cerebral cortex evoked by PTZ-induced seizures are quite unexpected. The present ﬁndings were
discussed analyzing the paradoxical effects of NPS: facilitation of convulsive behavior and protection against
oxidative damage to lipids and proteins.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Epilepsy is a chronic disorder characterized by recurrent seizures.
This is one of the most common neurological disorders with wide oc-
currence; the cumulative lifetime risks for epilepsy and for anyrmacologia Comportamental,
tro de Biociências, Campus
do Norte, 59078-970, Natal,
Biologia Celular e Molecular—
ense, 88806-000, Criciúma, SC,
i),
ier OA license.unprovoked seizure are 3.1% and 4.1%, respectively in industrialized
countries (McHugh and Delanty, 2008). The pathophysiology of epi-
lepsy is largely studied, and a growing body of evidence is suggesting
that prolonged seizures may result in mitochondrial dysfunction and
increased production of reactive oxygen species. These alterations
strongly affect neuronal excitability and synaptic neurotransmission,
which contributes to the generation of seizures (for a review see:
Folbergrová and Kunz, 2012; Patel, 2004). Additionally, neurons are
much more susceptible than other cells to free radical damage due
to the large lipid content of myelin sheaths and the high rate of
brain oxidative metabolism (Choi, 1993). One of the proposed mech-
anisms by which free radical generation can induce seizure activity is
its ability to inactivate the enzyme glutamine synthetase, thus abnor-
mally affecting the metabolism of the excitatory neurotransmitter
glutamate (Sudha et al., 2001).
Fig. 1. Experimental design employed to test the effects of NPS in PTZ-induced kindling
in mice.
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receptor antagonist, is considered an interesting and effective animal
model in the study of seizure mechanisms, and it is usable to predict
the effects of anticonvulsive drugs (Löscher, 2002). More importantly,
several studies have shown that PTZ administration produces damage
in macromolecules from neurons, such as DNA, proteins and lipids
(Akbas et al., 2005; Guzman et al., 2005; Ilhan et al., 2004, 2005; De
Oliveira et al., 2008).
Each year, 125,000 new cases of epilepsy are diagnosed but only 70%
of patients are effectively treated with currently available antiepileptic
drugs (Kwan and Brodie, 2007). For a substantial number of patients,
pharmacotherapies used today are not effective to control symptoms.
In view of that, there is a substantial need for more effective drugs
(Kwan and Brodie, 2007). Neuropeptides are potentmodulators of neu-
ronal excitability, which generally, under physiological conditions, are
“silent” and exert little effect on normal neurotransmission. However,
under conditions of excessively high neuronal ﬁring (i.e., epileptic sei-
zures), neuropeptides are released and exert modulatory effects on
neurotransmission (Hokfelt et al., 2000).
Neuropeptide S (NPS) is a 20 amino-acid peptide identiﬁed in the
brain and peripheral tissues of distinct species of vertebrates (Xu et al.,
2004). NPS is the endogenous ligand of a G protein-coupled receptor
named NPSR receptor (Xu et al., 2004). This novel peptidergic system
regulates several central biological functions, which includes anxiety
(Jüngling et al., 2008; Leonard et al., 2008; Rizzi et al., 2008; Vitale et
al., 2008), arousal (Rizzi et al., 2008; Xu et al., 2004), food intake (Beck
et al., 2005; Fedeli et al., 2009; Smith et al., 2006), locomotion (Pacheco
et al., 2011; Castro et al., 2009a, 2009b; Leonard et al., 2008; Mochizuki
et al., 2010; Okamura et al., 2008; Rizzi et al., 2008; Roth et al., 2006;
Smith et al., 2006; Xu et al., 2004), nociception (Li et al., 2009; Peng et
al., 2010), memory processing (Han et al., 2009; Okamura et al., 2011),
and motivational behaviors (Cannella et al., 2009; Cao et al., 2011).
It should be noted that the pattern of effects of NPS on sleep and
emotional behavior is quite unique. In fact, identical dose ranges of
NPS evoke, at the same range, anxiolysis and wakefulness, a property
that is found neither in the available anxiolytic drugs, such as benzo-
diazepines, nor in psychostimulant drugs, such as amphetamine and
cocaine. These latter drugs potently induce arousal, though simulta-
neously appear to be anxiogenic (for a review see: Reinscheid et al.,
2005). Thus, considering this quite paradoxical anxiolytic and
psychostimulant proﬁle of action of NPS in rodents, and the lack of in-
formation regarding the effects of NPS on seizures, this study investi-
gates the behavioral effects of NPS in mice submitted to the animal
model of seizures induced by the repeated administration of PTZ.
Studies on rodent animal models of seizure have shown an increase
in the generation of reactive oxygen and nitrogen species, which leads
to the oxidation of cellular macromolecules in brain areas (Bellissimo
et al., 2001; Erakovic et al., 2003; Freitas, 2009; Freitas et al., 2005). Ad-
ditionally, the involvement of free radicals in seizures is also supported
by reports showing antioxidants exogenously administered to protect
the brain against seizure-induced neuronal damage (Barros et al.,
2007; Santos et al., 2008; Tomé et al., 2010; Xavier et al., 2007).
Data from literature have suggested that NPS may have
neuroprotective effects. Okamura et al. (2010) showed that NPS
may have protective effects against the neurotoxic and behavioral
changes produced by NMDA receptor antagonists. Castro et al.
(2009a) showed that acute administration of NPS attenuates oxidative
damage to lipids and proteins produced by the i.c.v. procedure per se
in mice, and this effect of NPS against oxidative damage to lipids and
proteins was prevented by the administration of lithium and valproate
(Castro et al., 2009b). Nevertheless, no information is available about
the actions of NPS under chemical stimulus-induced macromolecule
oxidation. Thus, based on the context cited above, this study was
aimed to investigate the effects of NPS on the oxidative stress damage
induced by PTZ to macromolecules, such as proteins, lipids and DNA
in hippocampus and cerebral cortex.2. Material and methods
2.1. Materials
Pentylenetetrazole (PTZ) was purchased from Sigma-Aldrich (code
No. P6500). Human NPSwas synthesized by Dr R. Guerrini, Department
of Pharmaceutical Science and Biotechnology Center, University of Fer-
rara, according to published methods (Roth et al., 2006). NPS and PTZ
were dissolved in saline solution (NaCl 0.9%, w/v). All other chemicals
were of analytical reagent grade and purchased from local suppliers.
2.2. Animals
Male CF-1 mice (2–3 months, 45–55 g) were obtained from our
breeding colony (UNESC). The animals were housed six per cage
with food and water freely available and were maintained on a 12-h
light/dark cycle (lights on at 7:00 am). Each animal was used only
once. All experimental procedures involving animals were performed
in accordance with the Brazilian Law for the care and use of laborato-
ry animals. This study was approved by the local ethics committee
(Comitê de Ética em Pesquisa da Universidade do Extremo Sul
Catarinense; Protocol number: 332/2008).
2.3. Treatments
The PTZ-induced seizures treatment was based on the study of De
Oliveira et al. (2008). Animals were injected subcutaneously with PTZ
60 mg/kg or saline solution (NaCl 0.9%) once every three days, compris-
ing a total of six injections (last injection 16 days after the ﬁrst injection).
Injections were given between 7 and 11 a.m. In the last treatment day,
5 min before the injection of PTZ or saline, animals received 2 μL via
i.c.v. saline or NPS at distinct doses (1, 0.1 and 0.01 nmol). The i.c.v. injec-
tion was based on “free hand” technique as described by Laursen and
Belknap (1986), and previously adopted by our research group (Castro
et al., 2009a, 2009b). Brieﬂy, under light ether anesthesia (just enough
to promote the losing of the righting reﬂex), a 27-gauge needle attached
to a 10 μL Hamilton syringe was inserted perpendicularly 3 mm deep
through the skull, into the left ventricle, 2 mm laterally from themidline
on the line drawn through the anterior base of the ears.
In summary, as illustrated in Fig. 1, eight treatment groups were
employed in this study, as follows: (control) saline i.p.+saline i.c.v.;
(NPS 0.01) saline i.p.+NPS 0.01 nmol i.c.v.; (NPS 0.1) saline i.p.+NPS
0.1 nmol i.c.v.; (NPS 1) saline i.p.+NPS 1 nmol i.c.v.; (PTZ) PTZ
i.p.+saline i.c.v.; (PTZ+NPS 0.01) PTZ i.p.+NPS 0.01 nmol i.c.v.;
(PTZ+NPS 0.1) PTZ i.p.+NPS 0.1 nmol i.c.v.; (PTZ+NPS 1) PTZ
i.p.+NPS 1 nmol i.c.v.. Animals were injected twice (i.e. i.p. and i.c.v.)
only on the last treatment day. Thirtyminutes after the last PTZ injection,
Table 1
Frequency, duration and latency of seizures severity score III induced by PTZ after
treatment with NPS (via i.c.v., at doses ranging from 0.01 to 1 nmol).
Group Frequency of
seizures
Duration of seizures
(s)
Latency of seizure
(s)
PTZ+saline 65% (13/20) 4.92±3.85 539.6±475.6
PTZ+NPS 0.01 77.7% (14/18) 5.22±3.86 542.8±482.1
PTZ+NPS 0.1 83.3% (15/18) 7.05±4.02 475.0±362.5
PTZ+NPS 1 80% (12/15) 10.64±10.90⁎ 769.07±558.8
Numbers in parentheses indicate number of animals which showed seizure level III/
number of animals in that group. The latency time is from the ﬁrst seizure severity
III. Duration and latency of seizures are expressed as mean±S.D. Fisher's exact test
was used for analyzing the frequency of seizures; one-way ANOVA followed by Tukey's
test was used for analyzing the duration and latency of seizures.
⁎ Pb0.001 vs. PTZ group (n=15–20).
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tion, and cerebral cortex and hippocampus were dissected, to proceed
with biochemical analysis.
2.4. Behavioral analysis
After each PTZ or saline injection, animals were placed in acrylic
observation chambers for 30 min. During the behavioral assessment,
the following parameters were registered: latency to the ﬁrst seizure
severity score III, duration of the ﬁrst seizure severity score III (both in
seconds), and the number of seizures.
Additionally, convulsive behavior was rated according to the fol-
lowing scale (adapted from Da Silva et al., 1998): 0 = no convulsive
behavior; I = jerks of short duration; II = clonic forelimb convulsions
lasting less than 3 s; III = clonic forelimb convulsions lasting more
than 3 s; IV = generalized convulsions with tonic extension episodes
and full status epilepticus; V = death. In the present study, we used
in behavioral and biochemical assays only those animals which
presented seizures at a severity score rate≥ III.
2.5. Lipid peroxidation
Lipid peroxidation was measured by formation of thiobarbituric
acid (TBA) reactive substances (TBARS) according to published
methods (Esterbauer and Cheeseman, 1990) and previously adopted
by our research group (Castro et al., 2009a, 2009b). Data were
expressed as nmol of TBARS equivalents per mg of protein.
2.6. Protein carbonyl formation
Protein carbonyl content was measured in the brain homogenates
according to published methods (Levine et al., 1994) and previously
adopted by our research group (Castro et al., 2009a, 2009b). Protein
carbonyl levels were expressed as nmol of carbonyl per mg of protein.
2.7. Comet assay
Alkaline comet assay was carried out as described by Tice et al.
(2000) and previously adopted by our research group (Zugno et al.,
2008). The slides were stained with silver, as described by Nadin et
al. (2001), and analyzed under a microscope. Images of 100 randomly
selected cells from each animal (50 cells without choosing intention-
ally from each of two replicate slides) were analyzed. DNA migration
was determined visually by the categorization of comets into differ-
ent ‘classes’ of migration (Collins et al., 1997). All analyses were
performed by a blinded investigator.
2.8. Statistical analyses
Behavioral data are expressed asmean±SD of 15–20 animals/group
and biochemical data are presented as mean±SEM of 5–8 animals/
group. The comet assay was performed employing brain structures of
4–5 animals/group, and these data are presented as mean±SD. The
normality of variables was evaluated by the Kolmogorov–Smirnov
test. Duration and latency of convulsions between groups were ana-
lyzed by one-way ANOVA followed by Tukey's test, while the frequency
of PTZ-induced convulsions, expressed as the percentage (and the raw
number) of animals exhibiting score III convulsions were analyzed by
Fisher's Exact test. Differences among experimental groups at biochem-
ical analysis were determined by one-way ANOVA followed by
Duncan's test (oxidative damage to proteins and lipids) and Tukey's
test (comet assay). All statistical analyseswere performed using the sta-
tistical package SPSS 12.0 for Windows (SPSS, Inc., Chicago, IL, USA). In
all experiments, P-values lower than 0.05 were considered to be statis-
tically signiﬁcant.3. Results
Table 1 shows the percentage of animals repeatedly treated with
PTZ, which displayed seizure severity score III (i.e. clonic forelimb
convulsions lasting more than 3 s). Clonic seizure activity was de-
ﬁned as the seizure behaviors rated as scores III and IV. In our exper-
imental conditions, mice of the group PTZ showed seizure rated score
III (65%), and a non-signiﬁcant number of mice showed convulsive
behavior scored IV or V. The acute treatment with NPS at 0.01, 0.1
and 1 nmol, 30 min before the last injection of PTZ, neither modiﬁed
the number of animals which displayed seizure severity score III
(Table 1; P>0.05 for all comparisons; Fisher's Exact test) nor the la-
tency for the ﬁrst seizure severity score III (Table 1; P>0.05 for all
comparisons; ANOVA, Tukey's test). However, NPS at 1 nmol signiﬁ-
cantly increased the duration of seizures when compared to control
(Table 1; F(3.67)=3.16; P=0.03; ANOVA, Tukey's test).
The content of protein carbonyl formation and TBARS equivalents
in the hippocampus and cerebral cortex of mice treated with PTZ and
NPS, at increasing doses, is shown in Figs. 2 and 3, respectively. The
levels of protein carbonyl formation in the hippocampus and cerebral
cortex in mice treated with saline (i.p.) and NPS (i.c.v.) did not differ
from the control group (Fig. 2A and B, respectively). However, the
i.c.v. administration of NPS (in saline i.p. pretreated mice) reduced
signiﬁcantly TBARS equivalents in the hippocampus (Fig. 3A;
F(7.47)=22.71; Pb0.0001, ANOVA, Duncan's test), but not in the cere-
bral cortex (Fig. 3B).
It is important to note that the repeated administration of PTZ
caused a substantial increase in protein carbonyl formation in the
hippocampus and cerebral cortex of mice (Fig. 2A; F(7.21)=2.51,
P=0.048, and Fig. 2B; F(7.20)=9.07, Pb0.0001, respectively, ANOVA,
Duncan's test) and TBARS equivalent levels (Fig. 3A; F(7.47)=22.71,
Pb0.0001, and Fig. 3B; F(7.47)=12.19, Pb0.0001, ANOVA, Duncan's
test) in the same brain structures when compared to saline-treated
mice. Regarding the biochemical effects of NPS on PTZ-treated mice,
in the hippocampus, the i.c.v. administration of NPS 0.1 nmol before
the last injection of PTZ caused a statistically signiﬁcant decrease in
protein carbonyl formation (Fig. 2A; F(7.21)=2.51; P=0.048,
ANOVA, Duncan's test). Also in the hippocampus, the increase in
TBARS equivalent formation induced by PTZ was reduced by the
treatment with NPS at all doses tested (Fig. 3A; F(7.47)=22.71;
Pb0.0001, ANOVA, Duncan's test). A similar effect was observed in
the cerebral cortex, in which oxidative damage to proteins and lipids
evoked by PTZ was signiﬁcantly attenuated by NPS treatment
(Fig. 2B; F(7.20)=9.07, Pb0.0001 for carbonylated proteins; Fig. 3B;
F(7.47)=12.19; Pb0.0001 for lipid peroxidation; ANOVA, Duncan's
test).
Table 2 shows the effects of PTZ-induced seizures in mice treated
with NPS on DNA damage in the hippocampus and cerebral cortex.
In the cerebral cortex, the treatment with NPS before the last admin-
istration of PTZ did not affect the damage index and the frequency of
damage on DNA, when compared to the PTZ group (Table 2; P>0.05).
Fig. 2. Effects of the repeated i.p. administration of PTZ (60 mg/kg) and the i.c.v. injection of NPS (0.01, 0.1 and 1 nmol) on protein carbonyl content in the hippocampus (A) and
cerebral cortex (B) of mice assessed by a spectrophotometric assay. Data are shown as mean±S.E.M. (5–8 mice/group). *Pb0.05 vs. control group and #Pb0.05 vs. PTZ group,
according to one-way ANOVA followed by the Duncan's test.
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damage (i.e., damage index and damage frequency to DNA) only in
the hippocampus of PTZ-treated mice i.c.v. injected with NPS at the
higher dose when compared to PTZ plus saline (Table 2; F(3.16)=
21.45, Pb0.0001 for damage index, and F(3.16)=25.95, Pb0.0001 for
damage frequency; ANOVA, Tukey's test). Finally, it is worth men-
tioning that NPS per se, at all doses tested, did not induce any damage
to DNA in the cerebral cortex and hippocampus of mice (data not
shown).4. Discussion
The data herein presented could be summarized as follows: (1) a
high dose of NPS slightly increased the duration of class III seizures in-
duced by repeated administration of PTZ; (2) a range of doses of NPS at-
tenuated PTZ-induced oxidative damage to proteins and lipids in the
hippocampus and cerebral cortex; (3) NPS at the high dose increased
PTZ-induced DNA damage in the hippocampus (but not in the cerebral
cortex). A paradoxical effect for NPS was detected when analyzing the
presented data. In fact, NPS facilitated the effects of PTZ by increasing
the duration of seizures and DNA damage in the hippocampus, and, in
contrast, NPS attenuated the effects of PTZ-induced oxidative damage
to proteins and lipids in the hippocampus and cerebral cortex.Fig. 3. Effects of the repeated i.p. administration of PTZ (60 mg/kg) and the i.c.v. injection o
pocampus (A) and cerebral cortex (B) of mice assessed by a spectrophotometric assay. Data
vs. PTZ group, according to one-way ANOVA followed by the Duncan's test.Studies have suggested that the GABAergic (Rocha et al., 1996),
but also there is an involvement of glutamatergic (Jensen et al.,
1997), and adenosinergic systems (Pagonopoulou and Angelatou,
1998) are involved in PTZ-induced seizures. Additionally, alterations
in NMDA, kainite, A1 receptors and benzodiazepine binding site
densities were detected in the brain of mice repeatedly treated with
PTZ (Cremer et al., 2009).
Literature ﬁndings suggest a role for adenosinergic system in me-
diating the stimulatory effects of NPS in mice (Pacheco et al., 2011;
Boeck et al., 2010). Boeck et al. (2010) have showed that the blockade
of A2A receptors prevents the hyperlocomotion evoked by NPS.
Considering that the genetic and pharmacological blockade of A2A
receptors induces protective effects against PTZ-induced seizures
(El Yacoubi et al., 2008, 2009), it could be hypothesized that adeno-
sine is produced by NPS, and acting on A2A (a Gs/olf protein coupled
receptor), adenosine could mediate NPS-induced neuronal excitabil-
ity. Additionally, the expression of mRNA NPS–NPSR receptor sys-
tem can be modulated by acute and repeated treatment with
caffeine (Lage et al., 2006). Further studies aiming to investigate
the participation of A2A receptors in mediating the facilitatory action
of NPS in seizures induced by PTZ in mice are necessary.
Regarding the role of A1 receptors in the mediation of NPS-induced
stimulant effects, literature data have showed that the blockade of A1
receptors further increases the psychostimulant effect of NPS (Boeckf NPS (0.01, 0.1 and 1 nmol) on thiobarbituric acid reactive species (TBARS) in the hip-
are shown as mean±S.E.M. (5–8 mice/group). *Pb0.05 vs. control group and #Pb0.05
Table 2
Comet assay in brain tissue of PTZ-treated mice injected with NPS.
Group Parameters of DNA damage
Hippocampus Cerebral cortex
DI DF DI DF
PTZ+saline 52.0±9.2 21.0±3.4 201.7±31.1 54.0±7.9
PTZ+NPS 0.01 113.5±42.0 35.5±9.3 176.0±12.9 47.0±3.8
PTZ+NPS 0.1 175.0±16.9 52.3±3.3 170.0±35.3 52.8±8.8
PTZ+NPS 1 196.3±42.6⁎ 56.5±9.8⁎ 208.2±34.6 60.4±9.4
DI (damage index) can range from 0 (completely undamaged, 100 cells×0) to 400 (with
maximumdamage, 100×4). DF (damage frequency)was calculated based on the number
of cells with tail versus those with no tail. Data are expressed as mean±S.D.
⁎ Pb0.05 vs. PTZ group (n=4–5), according to one-way ANOVA followed by the
post-hoc Tukey's test.
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in the mouse brain are quite contrasting; in fact, Cremer et al. (2009)
have showed that A1 binding sites were down-regulated in the amygdala
and hippocampal CA1 region in PTZ-induced seizures inmice. In contrast,
Tchekalarova et al. (2005) showed that PTZ kindling induced up-
regulation of A1 receptor binding in cortex, hippocampus, amygdala
and geniculate nuclei. These contrasting differences could be due to the
protocol of PTZ-induced kindling used or the speciﬁc brain area analyzed
in these studies. Based on the available literature ﬁndings, it could be hy-
pothesized that PTZ-induced seizure could decrease A1 receptor densities
in the brain, thus reducing the inhibitory actions of adenosine on A1 re-
ceptors (a Gi/o protein coupled receptor) in NPS-induced stimulatory ef-
fects, thus evoking neuronal hyperexcitability. The effects described
above on A1 receptors could explain — together with the activation of
A2A receptor— the NPS-induced facilitatory effects on neuronal excitabil-
ity evoked by PTZ. On the other hand, considering that PTZ-induced kin-
dling increased adenosine A1 receptor binding sites (Tchekalarova et al.,
2005), the up-regulation of A1 receptors might represent a mechanism
for copingwith PTZ-induced damage tomacromolecules, and it could ex-
plain the protective effects of NPS against protein carbonyl formation and
lipid peroxidation evokedby PTZ. Indeed, the effects ofNPS (at high dose)
in slightly increasing the duration of PTZ-induced seizures could be due
to a ﬁnemodulation of adenosine by acting on stimulatory A2A and inhib-
itory A1 receptors.
It is worth mentioning that repeated seizures cause progressive
molecular and cellular changes in the brain, including activation of
glutamate receptors, and second messengers, besides the formation
of transcription factors (Li et al., 2000; Sejima et al., 1997). In this re-
gard, we should consider the fact that the effects of NPS (at the
highest dose) on duration of seizures could be mediated by other
neurotransmitters besides adenosine, including glutamate, acetylcho-
line, 5-HT, dopamine and/or corticotrophin-release factor. In fact,
these neurotransmitters have been reported to be involved in some
effects induced by NPS in the rodent brain (Jüngling et al., 2008;
Mochizuki et al., 2010; Okamura et al., 2010; Pañeda et al., 2009;
Raiteri et al., 2009; Si et al., 2010; Xu et al., 2007). An up-regulation
of NMDA receptors in the hippocampus and cerebral cortex in
PTZ-induced seizures has been previously reported (Cremer et al.,
2009; Jensen et al., 1997). Considering the NPS–NPSR receptor sys-
tem, it should be mentioned that NPS precursor is expressed in only
a few brainstem nuclei where it is co-expressed with various excit-
atory neurotransmitters, including glutamate (Xu et al., 2007). Addi-
tionally, Pape et al. (2010) showed that NPS increases release of
glutamate in synaptic circuits within the amygdala. No information
is available in the literature about the effects of NPS on glutamate re-
lease in the hippocampus and cerebral cortex, but considering the al-
teration in glutamate receptor densities evoked by PTZ-induced
kindling (Cremer et al., 2009; Jensen et al., 1997), we could hypothe-
sized that NPS at high dose could facilitate neuronal excitability and
damage to DNA due to the release of glutamate in the brain structurestriggered by PTZ. Studies aimed to investigate this hypothesis are
required.
It should be noted that the repeated administration of PTZ, under
our experimental conditions, induced damage to lipids and proteins in
the mouse hippocampus and cerebral cortex. These data are in line
with the literature, which reported an increase of oxidative stress to
macromolecules in the brain of mice (Patsoukis et al., 2005; Uma Devi
et al., 2006) and rats (Arora et al., 2010) repeatedly treated with PTZ.
Previously, it has been reported that NPS attenuates oxidative damage
to lipids and proteins induced by the i.c.v. injection procedure (Castro
et al., 2009a, 2009b). Interestingly, the present study showed for the
ﬁrst time the protective effects of NPS in PTZ-induced damage to mac-
romolecules, even at the NPS dose that increased duration of seizures
in PTZ-treated mice. The effects of NPS against PTZ-induced damage
to lipids and proteins could be explained by adaptative alterations
in antioxidant enzyme activity (catalase and superoxide dismutase)
(Castro et al., 2009a), which could evoke amechanism aimed to cope
with the neuronal damage induced by hyperexcitability. Another ex-
planation to this protective effect of NPS against damage to lipids
and proteins might involve ion ﬂux (Castro et al., 2009b). In fact,
the pretreatment with lithium and valproate, which affect directly
or indirectly Ca2+ and Na+ intracellular concentrations, prevents
the attenuation of oxidative damage to lipids and proteins evoked
by NPS (Castro et al., 2009b). As a ﬁnal point, in adenosine and
glutamate neurotransmitters could also be involved in mediating
the protective effects of NPS on damage to lipids and proteins
induced by PTZ.
The comet assay in brain tissue is useful in the investigation of the
genotoxic/antigenotoxic effects of drugs acting on the brain (Zugno et
al., 2008). The comet assay detects a broad spectrum of DNA lesions, in-
cluding double and single strand breaks (Tice et al., 2000). Our ﬁndings
showed that NPS did notmodify damage to DNA induced by the repeat-
ed administration of PTZ, but NPS, only at the dose which facilitated
PTZ-induced seizures, increased frequency of damage and damage
index on DNA in the hippocampus (but not cerebral cortex) of
PTZ-treated mice. The signiﬁcant increase in DNA damage evoked by
NPS 1 nmol could be due to the slight facilitatory effects of NPS in evok-
ing PTZ-induced seizures. It should bementioned that, at this point, we
are unawarewhether the increased DNA fragmentation observed in the
hippocampus by comet assay will persist, in which case the apoptosis
signaling pathway would consequently be activated, or the DNA dam-
age be repaired. Additional studies aimed to answer this question are
necessary to evaluate the putative detrimental effects of NPS on neuro-
nal survival.
Finally, we cannot rule out the involvement of other excitatory
neurotransmitters, such as dopamine and corticotrophin-release fac-
tor, in the facilitatory effects of NPS in the neuronal excitability
evoked by PTZ. In fact, the above mentioned neurotransmitters have
been reported to mediate the biological actions exerted by the i.c.v.
administration of NPS in the rodent brain (Mochizuki et al., 2010;
Pañeda et al., 2009; Si et al., 2010).
5. Conclusion
In conclusion, the present ﬁndings demonstrated that, from the be-
havioral standpoint, NPS administration, only at the high dose, slightly
facilitated neuronal excitability, which was observed by an increase in
duration of PTZ-induced seizure. Biochemical analysis revealed, for the
ﬁrst time, that NPS attenuated oxidative damage evoked by PTZ tomac-
romolecules, such as lipids and proteins, in the hippocampus and cere-
bral cortex. Concerning DNA, NPS was not effective in reducing DNA
fragmentation induced by PTZ; oppositely, NPS (at the high dose) in-
creased DNA damage only in the mouse hippocampus, thus suggesting
that DNA damage is correlated to proconvulsive effects of NPS. Alto-
gether, NPS displays little proconvulsive effects and, at the same
doses, prevents oxidative damage to lipids and proteins evoked by a
202 S.F. Ramos et al. / Pharmacology, Biochemistry and Behavior 103 (2012) 197–203chemical stimulus. Additional studies focused on investigating the
blockade of NPSR receptor signaling in animal models of seizure are
mandatory for understanding the participation of NPS–NPSR receptor
system in seizures.Acknowledgments
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